Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 18/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-3839 SCHEMBL29774125 | 1.00 | BACE1 (1.00) | BACE1KCNH2BACE2 | |
| Azd-3839 SCHEMBL29430228 | 1.00 | BACE1 (1.00) | BACE1KCNH2BACE2 | |
| Azd-3839 SCHEMBL1358778 | 1.00 | BACE1 (1.00) | BACE1KCNH2BACE2 | |
| Azd-3839 SCHEMBL1358428 | 1.00 | BACE1 (1.00) | BACE1KCNH2BACE2 | |
| Azd-3839 SCHEMBL12136074 | 1.00 | BACE1 (1.00) | BACE1KCNH2BACE2 | |
| Azd-3839 SCHEMBL30477099 | 1.00 | BACE1 (1.00) | BACE1KCNH2BACE2 | |
| Azd-3839 SCHEMBL2465855 | 0.95 | BACE1 (0.90) | BACE1KCNH2BACE2 | |
| SCHEMBL12191278 | 0.92 | BACE1 (0.86) | BACE1KCNH2BACE2 | |
| SCHEMBL12191257 | 0.92 | BACE1 (0.86) | BACE1KCNH2BACE2 | |
| SCHEMBL2465520 | 0.90 | BACE1 (0.82) | BACE1KCNH2BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | claimed |
| CN-102282140-A | New compounds 578 | — | 2011-12-14 | — | — | CN | claimed |
| US-20110281894-A1 | HEMIFUMARATE SALT | ASTRAZENECA AB (SE) | 2011-11-17 | — | — | US | claimed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | claimed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | claimed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | claimed |
| US-20210161910-A1 | Combining BACE1 Inhibitors With mGluR Agonists For Alzheimer's Disease Therapy | UNIVERSITY OF CONNECTICUT | 2021-06-03 | — | — | US | disclosed |
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | disclosed |
| CN-102282140-A | New compounds 578 | — | 2011-12-14 | — | — | CN | disclosed |
| US-20110281894-A1 | HEMIFUMARATE SALT | ASTRAZENECA AB (SE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281894-A1 | HEMIFUMARATE SALT | ASTRAZENECA AB (SE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281894-A1 | HEMIFUMARATE SALT | ASTRAZENECA AB (SE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281894-A1 | HEMIFUMARATE SALT | ASTRAZENECA AB (SE) | 2011-11-17 | — | — | US | disclosed |
| WO-2011142716-A1 | NOVEL HEMIFUMARATE SALT OF ISOINDOLE COMPOUND ACTING AS BACE INHIBITOR | ASTRAZENECA AB (SE) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011142716-A1 | NOVEL HEMIFUMARATE SALT OF ISOINDOLE COMPOUND ACTING AS BACE INHIBITOR | ASTRAZENECA AB (SE) | 2011-11-17 | — | — | WO | disclosed |
| US-8030500-B2 | Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281894-A1 | HEMIFUMARATE SALT | PSEN1, PSEN2, SNCA | BACE1 5/4885KCNH2 4502/4885BACE2 13/4885 |
| US-20100125082-A1 | NEW COMPOUNDS 578 | PSEN1, PSEN2, BACE1 | BACE1 3/4885KCNH2 4686/4885BACE2 10/4885 |
| US-20210161910-A1 | Combining BACE1 Inhibitors With mGluR Agonists For Alzheimer's Disease Therapy | BACE1, PSEN1, PSEN2 | BACE1 1/4885KCNH2 4316/4885BACE2 12/4885 |
| US-20110319426-A1 | Substituted Isoindoles | PSEN2, PSEN1, SNCA | BACE1 6/4885KCNH2 4588/4885BACE2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.